Tailoring LDL-C-Lowering Therapy to Patient Cardiovascular Risk: Identifying Effective Strategies for Patients with Diabetes

November 30, 2019

In this program, a panel of experts will discuss the latest guidelines for managing LDL-C in patients with diabetes, interpret data with nonstatin, LDL-C-lowering therapies, describe improving access to PCSK9 inhibitors and tips for achieving earlier access,

CME 2.00 Credits

Reducing LDL-C and Cardiovascular Risk with Nonstatin Therapy: From Evidence to Practice

July 02, 2019

In this symposium, lipid experts Dr. Robert Giugliano, Dr. Marc Sabatine, and Dr. James Underberg will describe best practices for internists in managing LDL-C and reducing the risk for major cardiovascular events with the addition of nonstatin therapy.

CME 2.00 Credits

Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice

April 22, 2019

In this program, an expert faculty will discuss the evidence and recommendations for managing LDL-C in patients with ASCVD, familial hypercholesterolemia (FH), diabetes, and those at increased cardiovascular risk without ASCVD.

CME 2.00 Credits

LDL-Cholesterol Lowering and Atherosclerotic Cardiovascular Disease Risk Reduction: Exploring the Evidence With Non-Statin Therapy

June 17, 2018

n this program, lipid experts will present, in state-of-the-art lectures and in 'realworld' interactive cases, optimal strategies and provide 'take-home' messages for reducing risk in patients with elevated LDL-C.

No Credit Available

Improving Outcomes in Patients with Elevated LDL-Cholesterol: A Case-Based Series

January 01, 2018

An informative expert series of lectures including cases with the goal of improving outcomes in patients with elevated LDL-cholesterol

No Credit Available

The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence-Based Treatment Strategies

November 08, 2016

In this educational initiative, experts will address the needs of cardiologists for 1) a grasp of the relationship between DM and HF and the pathophysiology of HF in DM, 2) an explanation of clinical evidence for HF drugs in patients with DM, and 3) an assessment of the profiles of traditional and newer antidiabetic agents in patients with/at risk for cardiovascular disease and interpretation of heart failure-related outcomes.

No Credit Available

Optimizing Management of Recurrent Angina after PCI

May 08, 2015

Deepak Bhatt, MD, MPH, FSCAI (Chair); Duane Pinto, MD, FSCAI and Peter Stone, MD, MPH conduct a state-of-the-art discussion and case study on recurrent angina after PCI

No Credit Available